|
Market Closed -
London S.E.
23:35:23 09/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1,750.00 GBX | +0.84% |
|
-1.66% | -4.08% |
| 10-10 | Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs | RE |
| 10-09 | Chai Discovery and GSK Announce Collaboration Following Successful Wet-Lab Evaluation | CI |
| Market Cap | 70.12B 92.79B 82.87B 77.09B 132B 8,981B 133B 928B 364B 4,579B 348B 341B 14,693B | P/E 2026 * |
13.6x | P/E 2027 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 91.33B 121B 108B 100B 172B 11,697B 173B 1,209B 474B 5,963B 454B 444B 19,137B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.5x |
| Free-Float |
92.75% | Yield 2026 * |
3.97% | Yield 2027 * | 4.27% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +0.84% | ||
| 1 week | -1.66% | ||
| Current month | -4.48% | ||
| 1 month | -1.16% | ||
| 3 months | -10.78% | ||
| 6 months | -19.58% | ||
| Current year | -4.08% |
| 1 week | 1,735.5 |  | 1,791 |
| 1 month | 1,735.5 | | 1,917 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/9/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 18/9/26 | Buy | Director | 768 | 0.0000% | ||
| 18/9/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.84% | -1.66% | +7.69% | +15.19% | 92.79B | |
| +0.83% | +3.19% | +41.49% | +94.83% | 1,051B | |
| +1.93% | +2.11% | +37.08% | +67.40% | 630B | |
| +1.49% | +5.19% | +19.94% | +85.13% | 489B | |
| +2.26% | +0.90% | +69.32% | +40.73% | 359B | |
| +1.45% | +3.50% | +23.29% | +40.84% | 344B | |
| +1.17% | +2.37% | +13.47% | +32.81% | 272B | |
| +0.89% | +1.08% | -6.13% | +9.63% | 246B | |
| +1.82% | +2.94% | +42.99% | +46.29% | 224B | |
| +2.77% | +4.44% | +29.01% | +96.43% | 187B | |
| Average | +1.54% | +2.41% | +27.82% | +52.93% | 389.65B | |
| Weighted average by Cap. | +1.46% | +2.82% | +32.74% | +65.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 44.88B 40.09B 37.29B 64.04B 4,344B 64.32B 449B 176B 2,215B 169B 165B 7,107B | 35.5B 46.98B 41.96B 39.03B 67.04B 4,547B 67.33B 470B 184B 2,318B 176B 173B 7,439B |
| Net income | 5.19B 6.87B 6.13B 5.71B 9.8B 665B 9.84B 68.68B 26.91B 339B 25.79B 25.23B 1,088B | 6.22B 8.23B 7.35B 6.83B 11.74B 796B 11.79B 82.25B 32.23B 406B 30.89B 30.21B 1,302B |
| Net Debt | 21.21B 28.07B 25.07B 23.32B 40.05B 2,716B 40.22B 281B 110B 1,385B 105B 103B 4,444B | 18.49B 24.47B 21.85B 20.33B 34.91B 2,368B 35.06B 245B 95.86B 1,207B 91.88B 89.87B 3,874B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/10/26 | GBX 1,750.00 | +0.84% | 6,931,381 |
| 08/10/26 | GBX 1,735.50 | -3.07% | 16,331,288 |
| 07/10/26 | GBX 1,790.50 | +1.42% | 5,172,881 |
| 06/10/26 | GBX 1,765.50 | +0.37% | 5,019,288 |
| 05/10/26 | GBX 1,759.00 | -1.15% | 3,780,146 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
